{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["28(22)"],"submitter":["Lim EA"],"funding":["AstraZeneca"],"pubmed_abstract":["Purpose
To evaluate AZD4635, an adenosine A2A receptor antagonist, as monotherapy or in combination with durvalumab in patients with advanced solid tumors.Patients and methods
In phase Ia (dose escalation), patients had relapsed/refractory solid tumors; in phase Ib (dose expansion), patients had checkpoint inhibitor-naïve metastatic castration-resistant prostate cancer (mCRPC) or colorectal carcinoma, non-small cell lung cancer with prior anti-PD-1/PD-L1 exposure, or other solid tumors (checkpoint-naïve or prior anti-PD-1/PD-L1 exposure). Patients received AZD4635 monotherapy (75-200 mg once daily or 125 mg twice daily) or in combination with durvalumab (AZD4635 75 or 100 mg once daily). The primary objective was safety; secondary objectives included antitumor activity and "],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pagination":["4871-4884"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9660540"],"repository":["biostudies-literature"],"pubmed_title":["Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors."],"pmcid":["PMC9660540"],"pubmed_authors":["George DJ","Moorthy G","Sachsenmeier KF","Bauer TM","Ulahannan S","Lim EA","Choe JH","Chen H","Karlix JL","Kumar R","Das M","Bendell JC","Patel MR","Falchook GS","Drake CG","Pouliot GP","Russell DL","Sidders BS","Hattersley MM","Pilling EA"],"additional_accession":[]},"is_claimable":false,"name":"Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.","description":"Purpose
To evaluate AZD4635, an adenosine A2A receptor antagonist, as monotherapy or in combination with durvalumab in patients with advanced solid tumors.Patients and methods
In phase Ia (dose escalation), patients had relapsed/refractory solid tumors; in phase Ib (dose expansion), patients had checkpoint inhibitor-naïve metastatic castration-resistant prostate cancer (mCRPC) or colorectal carcinoma, non-small cell lung cancer with prior anti-PD-1/PD-L1 exposure, or other solid tumors (checkpoint-naïve or prior anti-PD-1/PD-L1 exposure). Patients received AZD4635 monotherapy (75-200 mg once daily or 125 mg twice daily) or in combination with durvalumab (AZD4635 75 or 100 mg once daily). The primary objective was safety; secondary objectives included antitumor activity and ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2026-05-28T06:13:15.615Z","creation":"2025-04-04T14:18:40.42Z"},"accession":"S-EPMC9660540","cross_references":{"pubmed":["36044531"],"doi":["10.1158/1078-0432.CCR-22-0612"]}}